

Lance C Pagliaro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4411124/publications.pdf>

Version: 2024-02-01

52
papers

2,892
citations

257450

24
h-index

189892

50
g-index

55
all docs

55
docs citations

55
times ranked

3981
citing authors

#	ARTICLE	IF	CITATIONS
1	What Is the Most Effective Management of the Primary Tumor in Men with Invasive Penile Cancer: A Systematic Review of the Available Treatment Options and Their Outcomes. <i>European Urology Open Science</i> , 2022, 40, 58-94.	0.4	6
2	A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 22-31.e5.	1.9	8
3	Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ of the Bladder. <i>Journal of Urology</i> , 2021, 205, 1326-1335.	0.4	14
4	A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4746-4756.	7.0	22
5	Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience. <i>Prostate</i> , 2021, 81, 938-943.	2.3	4
6	Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6376-6383.	7.0	21
7	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3725-3736.	1.6	69
8	Collecting duct carcinoma: A single institution retrospective study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 13.e9-13.e18.	1.6	4
9	Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2012534.	5.9	72
10	Penile cancer with visceral metastasis and p16/human papillomavirus positivity: An unusual case of long-term survival. <i>Urology Case Reports</i> , 2020, 33, 101278.	0.3	2
11	Systematic Review and Meta-Analysis: Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma?. <i>Journal of Urology</i> , 2020, 203, 1147-1155.	0.4	39
12	Is there any benefit in adding postoperative adjuvant concurrent radiotherapy and chemotherapy for penile cancer with regional lymph node metastasis?. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 474-481.	3.9	9
13	Reply by Authors. <i>Journal of Urology</i> , 2020, 203, 1155-1155.	0.4	0
14	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. <i>JAMA Oncology</i> , 2019, 5, 1008.	7.1	526
15	Shared and unique genomic structural variants of different histological components within testicular germ cell tumours identified with mate pair sequencing. <i>Scientific Reports</i> , 2019, 9, 3586.	3.3	6
16	Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy. <i>Journal of Urology</i> , 2018, 200, 1075-1081.	0.4	5
17	Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2018, 200, 528-534.	0.4	59
18	Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e47-e57.	1.9	12

#	ARTICLE	IF	CITATIONS
19	Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist. <i>European Urology</i> , 2018, 73, 304-305.	1.9	1
20	Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1117-e1122.	1.9	1
21	Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 431-437.	3.9	20
22	Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. <i>European Urology</i> , 2017, 72, 660-664.	1.9	77
23	Factors associated with regional recurrence after lymph node dissection for penile squamous cell carcinoma. <i>BJU International</i> , 2017, 119, 591-597.	2.5	15
24	Non-seminomatous germ cell tumor with bone metastasis only at diagnosis: A rare clinical presentation. <i>Asian Journal of Urology</i> , 2017, 4, 124-127.	1.2	3
25	New Developments and Challenges in Rare Genitourinary Tumors: Non-Urothelial Bladder Cancers and Squamous Cell Cancers of the Penis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 330-336.	3.8	5
26	Low hypoxia inducible factor-1 \pm (HIF-1 \pm) expression in testicular germ cell tumors â€” a major reason for enhanced chemosensitivity?. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2017, 29, 374-378.	2.2	8
27	Clinically Meaningful Use of Blood Tumor Markers in Oncology. <i>BioMed Research International</i> , 2016, 2016, 1-10.	1.9	49
28	Multimodal Therapy in the Management of Advanced Penile Cancer. <i>Urologic Clinics of North America</i> , 2016, 43, 469-479.	1.8	1
29	Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. <i>Cancer</i> , 2016, 122, 1836-1843.	4.1	39
30	Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy. <i>BJU International</i> , 2016, 117, 118-125.	2.5	57
31	Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study. <i>Urology</i> , 2016, 89, 83-89.	1.0	17
32	Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 166.e21-166.e29.	1.6	44
33	Reply. <i>Urology</i> , 2015, 85, 1110.	1.0	0
34	Treatment for Metastatic Penile Cancer After First-line Chemotherapy Failure: Analysis of Response and Survival Outcomes. <i>Urology</i> , 2015, 85, 1104-1110.	1.0	64
35	Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. <i>Cancer Research</i> , 2015, 75, 4131-4142.	0.9	38
36	Implications for human papillomavirus in penile cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 53.e1-53.e8.	1.6	53

#	ARTICLE	IF	CITATIONS
37	Invasive extramammary Paget's disease of the bladder diagnosed 18years after noninvasive extramammary Paget's disease of the vulva. <i>Gynecologic Oncology Case Reports</i> , 2014, 8, 27-29.	0.9	7
38	Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3621-3630.	7.0	350
39	Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. <i>European Journal of Endocrinology</i> , 2013, 169, 891-899.	3.7	235
40	Penile Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 594-615.	4.9	149
41	Systemic therapy for sarcomatoid renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 913-920.	2.4	8
42	Rhabdomyolysis in a Prostate Cancer Patient Taking Ketoconazole and Simvastatin: Case Report and Review of the Literature. <i>Annals of Pharmacotherapy</i> , 2011, 45, 276-276.	1.9	9
43	Neoadjuvant Paclitaxel, Ifosfamide, and Cisplatin Chemotherapy for Metastatic Penile Cancer: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3851-3857.	1.6	307
44	Multimodality therapy in penile cancer: when and which treatments?. <i>World Journal of Urology</i> , 2009, 27, 221-225.	2.2	70
45	Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 487-491.	1.6	10
46	A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. <i>Cancer</i> , 2003, 97, 2988-2994.	4.1	39
47	Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003, 21, 456-462.	1.6	36
48	Repeated Intravesical Instillations of an Adenoviral Vector in Patients With Locally Advanced Bladder Cancer: A Phase I Study of <i>p53</i> Gene Therapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 2247-2253.	1.6	139
49	Cisplatin, Gemcitabine, and Ifosfamide As Weekly Therapy: A Feasibility and Phase II Study of Salvage Treatment for Advanced Transitional-Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2965-2970.	1.6	69
50	A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2000, 89, 615-618.	4.1	44
51	Gene therapy for bladder cancer. <i>World Journal of Urology</i> , 2000, 18, 148-151.	2.2	39
52	Rational Second-Generation Antiandrogen Use in Prostate Cancer. <i>Oncologist</i> , 0, , .	3.7	10